September 2024 in “Journal of the American Academy of Dermatology” This study addresses the scarcity of information on the effectiveness and safety of low-dose oral minoxidil for treating COVID-19-associated telogen effluvium, a type of hair loss observed in some patients after COVID-19 infection, but does not report specific results.
This study found a high prevalence of telogen effluvium among patients hospitalized for severe COVID-19, with most experiencing early onset and eventual complete hair regrowth.
March 2023 in “Journal of Cosmetic Dermatology” This study suggests that capillarectasia, or dilation of scalp capillaries, may help distinguish COVID-19-associated telogen effluvium from classic acute telogen effluvium.
February 2025 in “Indus journal of bioscience research.” In this descriptive cross-sectional study conducted at a Karachi hospital, researchers found a high prevalence of Telogen Effluvium in female COVID-19 survivors, particularly those with diabetes, and noted that dietary supplementation may be linked to reduced hair loss severity post-infection.
This review discusses the link between COVID-19 and diffuse hair loss, focusing on the potential of proteoglycan replacement therapy with Nourkrin® to treat pattern hair loss and telogen effluvium in affected patients, and reports no new clinical results.
